Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.46 |
| ▸ | PLK1 | P53350 | 4/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347447 | 0.83 | PTGER4 (0.56) | CYSLTR2CYSLTR1TRPV1MAPTCRHBP | |
| SCHEMBL6342169 | 0.82 | FFAR1 (0.50) | S1PR1S1PR3L3MBTL1 | |
| SCHEMBL27606842 | 0.76 | L3MBTL1 (0.54) | TRPV1MAPTCRHBPRAB9ACRHR2 | |
| SCHEMBL5363290 | 0.76 | PLK1 (0.52) | CYSLTR2CYSLTR1MAPTCRHBPRAB9A | |
| SCHEMBL5346187 | 0.76 | PTGER4 (0.60) | TRPV1MAPTCRHBPRAB9ACRHR2 | |
| SCHEMBL6705756 | 0.76 | KCNQ2 (0.60) | MAPTCRHBPCRHR2NPSR1L3MBTL1 | |
| SCHEMBL2985340 | 0.75 | FFAR1 (0.47) | TRPV1MAPTCRHBPRAB9ACRHR2 | |
| SCHEMBL27606877 | 0.75 | LMNA (0.47) | TRPV1MAPTCRHBPRAB9ACRHR2 | |
| SCHEMBL27606841 | 0.75 | MAPT (0.50) | MAPTCRHBPRAB9ACRHR2NPSR1 | |
| SCHEMBL2984631 | 0.74 | PTGER4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835752-B2 | Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-28 | — | — | US | claimed |
| US-20030216381-A1 | Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1312601-A1 | CARBOXYLIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-21 | — | — | EP | claimed |
| US-20050026908-A1 | Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical aggents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-02-03 | — | — | US | disclosed |
| US-6835752-B2 | Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-28 | — | — | US | disclosed |
| US-20030216381-A1 | Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1312601-A1 | CARBOXYLIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026908-A1 | Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical aggents comprising the same as active ingredient | PTGER4, PTGER3, LTB4R | CYSLTR2 18/4885CYSLTR1 8/4885TRPV1 99/4885 |
| US-20030216381-A1 | Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient | PTGER4, PTGER1, PTGER2 | CYSLTR2 18/4885CYSLTR1 11/4885TRPV1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.